查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024201

照護現場分子診斷市場：按應用、技術、施行地點、產品和國家分類－附執行指南和分析（2026-2030 年）

Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Analysis 2026 - 2030
出版日期: | 出版商: Howe Sound Research | 英文 520 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

報告摘要：

這個快速成長的市場還能進一步擴張嗎？您可以在這份關於「照護現場分子診斷」的綜合報告中找到所有相關資訊。

照護現場分子診斷是體外診斷（IVD）產業成長最快的領域之一，它結合了核酸檢測的高分析靈敏度和分散式醫療服務的速度與便利性。分子診斷技術透過檢測與病原體和遺傳生物標記相關的DNA和RNA，能夠實現疾病的高精度早期檢測。即時分子診斷系統旨在患者照護地點或附近快速提供檢測結果，從而減少對中心檢查室的依賴，並支持及時的臨床決策。

全球即時分子診斷市場預計在2025年達到約49億美元，預計到2030年將達到72億美元，複合年成長率為7.8%。這一成長主要受以下因素驅動：對感染疾病快速診斷的需求不斷成長、分散式醫療模式的擴展、小型化分子檢測技術的進步以及對簡化臨床工作流程日益重視。

即時分子診斷在臨床環境中尤其重要，因為快速診斷能夠直接影響治療決策，例如急診、急診、診所、藥局和門診部。快速檢測有助於及早啟動適當的治療，並有可能減少不必要的頻譜抗生素使用。

新冠疫情提高了人們對快速分子診斷檢測重要性的認知，並加速了攜帶式分子檢測平台的發展。分散式分子診斷設備的部署有望支持除新冠病毒以外的其他傳染病檢查的持續成長。

技術概述

即時分子診斷系統採用核酸擴增技術，並針對簡化的工作流程和分散式環境進行了最佳化。聚合酵素鏈鎖反應（PCR）因其高靈敏度和特異性，仍是應用最廣泛的技術之一。即時PCR能夠快速檢測和定量臨床檢體中的病原體遺傳物質。

恒溫環型核酸擴增（LAMP）、解旋酶依賴性擴增（HDA）和重組聚合酵素擴增（RPA）等等溫擴增技術無需複雜的循環設備即可進行分子檢測。這些技術有助於開發對儀器要求簡化的攜帶式檢測設備。

微流體技術透過將樣品製備、擴增和檢測整合到盒式系統中，實現了實驗室流程的小型化。

此全整合分子診斷試劑盒減少了人工檢體處理的需要，並將污染風險降至最低。

檢測化學技術的進步提高了分析靈敏度，縮短了獲得結果所需的時間。

此連接功能允許將測試結果傳輸到實驗室資訊系統和電子健康記錄。

與數位健康平台的整合能夠為臨床決策和流行病學監測提供支援。

主要用途

傳染病檢查是即時分子診斷技術最大的應用領域。呼吸道傳染病檢查廣泛用於檢測流感病毒、呼吸道融合細胞病毒（RSV）、SARS-CoV-2和其他呼吸道病原體。

性行為感染感染 (STI) 檢測是另一個重要的應用領域，包括檢測沙眼披衣菌和淋病奈瑟菌等病原體。

胃腸道傳染病檢查可以檢測出與腹瀉疾病相關的病原體。

醫療相關感染檢測有助於醫院和門診診所進行感染控制工作。

即時分子診斷也可用於檢測抗菌素抗藥性標記。

新的應用領域包括分散環境下的基因檢測和腫瘤生物標記的檢測。

快速診斷結果有助於改善患者分診和治療方法選擇。

即時分子檢測有可能減少後續就診的需要，並提高病患的便利性。

市場促進因素

推動即時分子診斷市場成長的因素有很多。

對快速診斷結果日益成長的需求正在推動分散式檢查解決方案的普及。

醫療保健系統需要能夠提高工作流程效率和縮短病患等待時間的技術。

人們對抗藥性的認知不斷提高，對準確鑑定病原體的需求也隨之增加。

分子生物學技術的進步使得開發小型診斷設備成為可能。

隨著門診服務的擴展，對在患者身邊進行檢查的能力的需求也日益成長。

診斷和數位健康平台的整合提高了連接性和數據管理能力。

醫療服務提供者正在尋求能夠支持及時臨床決策的工具。

對感染疾病防治投入的增加正在推動快速分子檢測技術的應用。

醫療服務分散化正在推動即時檢測的普及。

市場區隔

POC分子診斷市場可以按技術、應用、最終用戶和地區進行細分。

從技術角度來看，基於 PCR 的系統佔據了市場的大部分佔有率，其次是等溫擴增技術，然後是新興的分子檢測方法。

依應用領域分類，傳染病檢查佔比最大，尤其是呼吸道傳染病檢查。其他領域包括性行為感染感染、胃腸道感染疾病和院內獲得性感染。

最終用戶包括醫院、診所、急診室、藥局和其他醫療機構。

北美是重要的區域市場，這得益於其先進的醫療保健基礎設施和較高的診斷技術普及率。

歐洲已成為一個重要的市場，這得益於其對醫療創新的投入。

由於對醫療基礎設施和診斷技術的投資增加，亞太市場正在擴張。

在新興市場，集中檢測設施有限，攜帶式診斷技術可能很有益。

競爭格局

POC分子診斷市場包括跨國診斷公司、專業分子診斷開發公司和新興生物技術公司。

競爭程度取決於靈敏度、特異性、易用性、所需時間以及所提供的測試選項的廣度等因素。

設備安裝策略通常涉及長期耗材供應合約。

測試盒帶來的經常性收入是經營模式的關鍵要素。

各公司正日益開發將設備、耗材和軟體結合的整合診斷平台。

數位化連結正成為一項重要的差異化因素。

診斷設備製造商與醫療服務提供者之間的策略合作能夠促進產品推廣應用。

試劑盒設計和檢測化學的創新會影響競爭地位。

未來展望

隨著醫療保健系統越來越重視快速診斷和分散式醫療服務，POC分子診斷市場預計將繼續擴張。

多重分子偵測板有潛力擴展分散式環境下的診斷能力。

微流體和生物感測器技術的進步可能會催生出更小的分子診斷平台。

人工智慧（AI）工具具有提高分子診斷資料解讀能力的潛力。

與遠端醫療平台的整合有望支援遠距患者管理。

感染疾病監測計劃的擴展可能會導致快速分子檢測技術的廣泛應用。

整體而言，即時分子診斷可在患者照護環境中提供快速且準確的診斷訊息，成為現代醫療保健服務的重要組成部分。分子生物學技術的持續進步以及與數位醫療的融合預計將推動市場持續成長。

目錄

第1章 市集指南

  • 戰略情勢分析
  • 企業主管、行銷負責人和業務拓展負責人。
  • 管理顧問和投資顧問指南
  • 人工智慧的影響

第2章：引言與市場定義

  • 臨床實務中的分子診斷是什麼？
  • 診斷革命
  • 市場定義
  • 調查方法
  • 觀點：醫療費用支出

第3章：測量儀器、自動化和診斷的發展趨勢

  • 測量與自動化

第4章 行業概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 測量儀器供應商
    • 化學品/試劑供應商
    • 病理檢測用品供應商
    • 獨立臨床實驗室
    • 國家/地區公共研究機構
    • 醫院檢查室
    • 醫師診所檢查室（POLS）
    • 審計機構
    • 認證機構
  • 臨床檢測市場細分
  • 產業結構

第5章：主要MDx公司概況

  • Abbott Laboratories
  • Abionic
  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Alveo Technologies
  • Anitoa
  • Applied BioCode
  • Aureum Diagnostics
  • Aus Diagnostics
  • Autonomous Medical Devices
  • Baebies
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • BioFire Diagnostics（bioMerieux）
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid（Danaher）
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis（OpGen）
  • Detect
  • Diagenode Diagnostics（Hologic）
  • Diasorin SpA
  • DNAe
  • Domus Diagnostics
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx（Roche）
  • Genomadix
  • Getlabs
  • Global Access Diagnostics
  • Grip Molecular Technologies
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Iollo
  • J&J Innovative Medicine
  • Karius
  • Lucira Health（Pfizer）
  • LumiraDx
  • Maxim Biomedical
  • Meep
  • Meridian Bioscience
  • Millipore Sigma
  • Molbio Diagnostics
  • NanoDx
  • Nanomix
  • Novacyt
  • Novel Microdevices
  • Novus Diagnostics
  • Nuclein
  • OnsiteGene
  • Operon
  • OraSure Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Prenetics
  • Primerdesign（Novacyt）
  • Prominex
  • Proof Diagnostics
  • Qiagen
  • QuantuMDx
  • QuidelOrtho
  • R-Biopharm AG
  • Response Biomedical
  • Revvity
  • Roche Diagnostics
  • Salignostics
  • SD Biosensor
  • Seegene
  • Sekisui Diagnostics
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Talis Biomedical
  • Thermo Fisher Scientific
  • Uniogen
  • Veramarx
  • Veredus Laboratories
  • XCR Diagnostics
  • Zhejiang Orient Gene Biotech

第6章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素

第7章 分子診斷－感染疾病的最新進展

第8章：全球照護現場分子診斷市場

  • 全球市場概覽（按國家/地區分類）
  • 全球市場概覽（按應用領域分類）
  • 全球市場概覽（依技術分類）
  • 全球市場概覽（施行地點）
  • 全球市場概覽（按產品類別分類）

第9章 全球即時分子診斷市場－依應用照護現場

  • 呼吸道感染疾病
  • 胃腸道感染疾病
  • 性行為感染傳染病
  • 其他

第10章：全球即時分子診斷市場－依技術照護現場

  • PCR
  • NGS/探針
  • 其他

第11章 全球照護現場分子診斷市場－按施行地點

  • 醫院醫療實踐
  • 診所或醫生辦公室的檢查室
  • 老人設施
  • 其他

第12章 全球照護現場分子診斷市場－依產品分類

  • 裝置
  • 墨水匣
  • 其他

第13章附錄

表格一覽

圖表列表

簡介目錄
Product Code: POCMDx 426

Report Overview:

Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Point-of-Care (POC) Molecular Diagnostics represent one of the fastest growing segments of the in vitro diagnostics (IVD) industry, combining the analytical sensitivity of nucleic acid-based testing with the speed and convenience of decentralized healthcare delivery. Molecular diagnostic technologies detect DNA or RNA associated with pathogens or genetic biomarkers, enabling highly accurate detection of disease at early stages. POC molecular systems are designed to deliver results rapidly at or near the site of patient care, reducing dependence on centralized laboratories and supporting timely clinical decision-making.

The global POC molecular diagnostics market is estimated to be approximately USD 4.9 billion in 2025 and is projected to grow at compound annual growth rates of 7.8% reaching 7.2 billion in 2030. Growth is driven by increasing demand for rapid infectious disease diagnosis, expansion of decentralized healthcare models, advances in miniaturized molecular testing technologies, and increasing emphasis on improving clinical workflow efficiency.

POC molecular diagnostics are particularly valuable in clinical environments where rapid diagnosis can influence immediate treatment decisions, including emergency departments, urgent care centers, physician offices, pharmacies, and outpatient clinics. Rapid testing enables earlier initiation of appropriate therapies and may reduce unnecessary use of broad-spectrum antibiotics.

The COVID-19 pandemic increased awareness of the importance of rapid molecular diagnostic testing and accelerated development of portable molecular testing platforms. The installed base of decentralized molecular diagnostic instruments is expected to support continued growth in non-COVID infectious disease testing applications.

Technology Overview

POC molecular diagnostic systems use nucleic acid amplification technologies adapted for simplified workflows and decentralized environments. Polymerase chain reaction (PCR) remains one of the most widely used technologies due to high sensitivity and specificity. Real-time PCR enables rapid detection and quantification of pathogen genetic material in clinical samples.

Isothermal amplification technologies such as loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), and recombinase polymerase amplification (RPA) enable molecular testing without complex thermal cycling equipment. These technologies support development of portable testing devices with simplified instrument requirements.

Microfluidics technologies enable miniaturization of laboratory processes into cartridge-based systems that integrate sample preparation, amplification, and detection steps.

Fully integrated molecular diagnostic cartridges reduce need for manual sample processing and minimize contamination risk.

Advances in assay chemistry are improving analytical sensitivity and reducing time to result.

Connectivity features enable transmission of test results to laboratory information systems or electronic health records.

Integration with digital health platforms may support clinical decision-making and epidemiological monitoring.

Key Applications

Infectious disease testing represents the largest application segment for POC molecular diagnostics. Respiratory infection testing is widely used to detect pathogens such as influenza virus, respiratory syncytial virus (RSV), SARS-CoV-2, and other respiratory organisms.

Sexually transmitted infection (STI) testing represents another important application area, including detection of pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae.

Gastrointestinal infection testing enables detection of pathogens associated with diarrheal disease.

Healthcare-associated infection testing supports infection control efforts in hospitals and outpatient care settings.

POC molecular diagnostics may also be used for detection of antimicrobial resistance markers.

Emerging applications include genetic testing and oncology biomarker detection in decentralized settings.

Rapid diagnostic results may support improved patient triage and treatment selection.

POC molecular testing may reduce need for follow-up visits and improve patient convenience.

Market Drivers

Several factors are driving growth in the POC molecular diagnostics market.

Increasing demand for rapid diagnostic results is supporting adoption of decentralized testing solutions.

Healthcare systems are seeking technologies that improve workflow efficiency and reduce patient wait times.

Growing awareness of antimicrobial resistance is increasing demand for accurate pathogen identification.

Advances in molecular biology technologies are enabling development of compact diagnostic devices.

Expansion of outpatient care settings is increasing need for near-patient diagnostic capabilities.

Integration of diagnostics with digital health platforms is improving connectivity and data management.

Healthcare providers are seeking tools that support timely clinical decision-making.

Increased investment in infectious disease preparedness is supporting adoption of rapid molecular testing technologies.

Decentralization of healthcare delivery is supporting expansion of point-of-care testing.

Market Segmentation

The POC molecular diagnostics market can be segmented by technology, application, end user, and geographic region.

By technology, PCR-based systems represent a significant portion of the market, followed by isothermal amplification technologies and emerging molecular detection methods.

By application, infectious disease testing represents the largest segment, particularly respiratory infection testing. Additional segments include sexually transmitted infections, gastrointestinal infections, and hospital-acquired infections.

End users include hospitals, physician offices, urgent care clinics, pharmacies, and other healthcare environments.

North America represents a major regional market due to advanced healthcare infrastructure and high adoption of diagnostic technologies.

Europe represents a significant market supported by healthcare innovation initiatives.

Asia-Pacific markets are expanding due to increasing investment in healthcare infrastructure and diagnostic technologies.

Emerging markets may benefit from portable diagnostic technologies due to limited access to centralized laboratories.

Competitive Landscape

The POC molecular diagnostics market includes multinational diagnostic companies, specialized molecular diagnostics developers, and emerging biotechnology firms.

Competition is influenced by test sensitivity, specificity, ease of use, turnaround time, and breadth of test menu.

Instrument placement strategies often involve long-term consumable supply agreements.

Recurring revenue from test cartridges represents an important component of business models.

Companies are increasingly developing integrated diagnostic platforms combining instrumentation, consumables, and software.

Digital connectivity features are becoming important differentiators.

Strategic partnerships between diagnostic companies and healthcare providers support product adoption.

Innovation in cartridge design and assay chemistry influences competitive positioning.

Future Outlook

The POC molecular diagnostics market is expected to continue expanding as healthcare systems emphasize rapid diagnosis and decentralized care delivery.

Multiplex molecular testing panels may expand diagnostic capabilities within decentralized environments.

Advances in microfluidics and biosensor technologies may further miniaturize molecular diagnostic platforms.

Artificial intelligence tools may improve interpretation of molecular diagnostic data.

Integration with telehealth platforms may support remote patient management.

Expansion of infectious disease surveillance programs may increase adoption of rapid molecular testing.

Overall, point-of-care molecular diagnostics represent an important component of modern healthcare delivery, providing rapid and accurate diagnostic information at the time of patient care. Continued advances in molecular biology technologies and digital health integration are expected to support sustained market growth.

Table of Contents

1 Market Guides

  • 1.1 Strategic Situation Analysis
    • 1.1.1 Strategic Role in Rapid Clinical Decision-Making
    • 1.1.2 Technology Platforms and Innovation
    • 1.1.3 Cost Structure and Economic Considerations
    • 1.1.4 Test Menu Expansion and Clinical Utility
    • 1.1.5 Regulatory and Quality Requirements
    • 1.1.6 Competition from Centralized Laboratory Testing
    • 1.1.7 Workflow Integration and Ease of Use
    • 1.1.8 Competitive Landscape and Industry Structure
    • 1.1.9 Geographic Market Dynamics
    • 1.1.10 Outlook and Strategic Implications
  • 1.2 Guide for Executives, Marketing and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors
  • 1.4 Impact of Artificial Intelligence

2 Introduction and Market Definition

  • 2.1 What are Molecular Diagnostics at the Point of Care?
  • 2.2 The Diagnostics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenues
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare Spending
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Healthcare and Pharmaceuticals
    • 2.5.3 Spending on Diagnostics
    • 2.5.4 Important Role of Insurance for Medical Services

3 Instrumentation, Automation and Diagnostic Trends

  • 3.1 Instrumentation and Automation
    • 3.1.1 Traditional Automation and Centralization
    • 3.1.2 The New Automation, Decentralization and Point Of Care
    • 3.1.3 Instruments Key to Market Share
    • 3.1.4 Bioinformatics Plays a Role
    • 3.1.5 PCR Takes Command
    • 3.1.6 Next Generation Sequencing Fuels a Revolution
    • 3.1.7 NGS Impact on Pricing
    • 3.1.8 Whole Genome Sequencing, A Brave New World
    • 3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

  • 5.1 Abbott Laboratories
  • 5.2 Abionic
  • 5.3 Accelerate Diagnostics
  • 5.4 Access Bio
  • 5.5 Ador Diagnostics
  • 5.6 ADT Biotech
  • 5.7 Akonni Biosystems
  • 5.8 Alveo Technologies
  • 5.9 Anitoa
  • 5.10 Applied BioCode
  • 5.11 Aureum Diagnostics
  • 5.12 Aus Diagnostics
  • 5.13 Autonomous Medical Devices
  • 5.14 Baebies
  • 5.15 Beckman Coulter Diagnostics (Danaher)
  • 5.16 Becton, Dickinson and Company
  • 5.17 Binx Health
  • 5.18 Biocartis
  • 5.19 BioFire Diagnostics (bioMerieux)
  • 5.20 bioMerieux Diagnostics
  • 5.21 Bio-Rad Laboratories, Inc
  • 5.22 Bosch Healthcare Solutions GmbH
  • 5.23 Cepheid (Danaher)
  • 5.24 Credo Diagnostics Biomedical
  • 5.25 Cue Health
  • 5.26 Curetis (OpGen)
  • 5.27 Detect
  • 5.28 Diagenode Diagnostics (Hologic)
  • 5.29 Diasorin S.p.A.
  • 5.30 DNAe
  • 5.31 Domus Diagnostics
  • 5.32 Enzo Biochem
  • 5.33 Eurofins Scientific
  • 5.34 Fluxergy
  • 5.35 Fusion Genomics.
  • 5.36 Genedrive
  • 5.37 Genetic Signatures
  • 5.38 GenMark Dx (Roche)
  • 5.39 Genomadix
  • 5.40 Getlabs
  • 5.41 Global Access Diagnostics
  • 5.42 Grip Molecular Technologies
  • 5.43 Hologic
  • 5.44 Immunexpress
  • 5.45 Inflammatix
  • 5.46 Invetech
  • 5.47 Iollo
  • 5.48 J&J Innovative Medicine
  • 5.49 Karius
  • 5.50 Lucira Health (Pfizer)
  • 5.51 LumiraDx
  • 5.52 Maxim Biomedical
  • 5.53 Meep
  • 5.54 Meridian Bioscience
  • 5.55 Millipore Sigma
  • 5.56 Molbio Diagnostics
  • 5.57 NanoDx
  • 5.58 Nanomix
  • 5.59 Novacyt
  • 5.60 Novel Microdevices
  • 5.61 Novus Diagnostics
  • 5.62 Nuclein
  • 5.63 OnsiteGene
  • 5.64 Operon
  • 5.65 OraSure Technologies
  • 5.66 Oxford Nanopore Technologies
  • 5.67 Panagene
  • 5.68 Prenetics
  • 5.69 Primerdesign (Novacyt)
  • 5.70 Prominex
  • 5.71 Proof Diagnostics
  • 5.72 Qiagen
  • 5.73 QuantuMDx
  • 5.74 QuidelOrtho
  • 5.75 R-Biopharm AG
  • 5.76 Response Biomedical
  • 5.77 Revvity
  • 5.78 Roche Diagnostics
  • 5.79 Salignostics
  • 5.80 SD Biosensor
  • 5.81 Seegene
  • 5.82 Sekisui Diagnostics
  • 5.83 Siemens Healthineers
  • 5.84 Sona Nanotech
  • 5.85 SpeeDx
  • 5.86 T2 Biosystems
  • 5.87 Talis Biomedical
  • 5.88 Thermo Fisher Scientific
  • 5.89 Uniogen
  • 5.90 Veramarx
  • 5.91 Veredus Laboratories
  • 5.92 XCR Diagnostics
  • 5.93 Zhejiang Orient Gene Biotech

6 Market Trends

  • 6.1 Factors Driving Growth
    • 6.1.1 New Genotypes Creating New Markets
    • 6.1.2 Aging Population a Boon for All Diagnostics
    • 6.1.3 Developing World Driving ID Dx Growth
    • 6.1.4 Point of Care - Why Centralization is Losing Steam
    • 6.1.5 Self Testing
    • 6.1.6 The Need for Speed
  • 6.2 Factors Limiting Growth
    • 6.2.1 Lower Costs
    • 6.2.2 Infectious Disease is Declining
    • 6.2.3 Wellness Hurts
    • 6.2.4 Economic Growth improves Living Standards

7 Molecular Dx - Infectious Disease Recent Developments

  • 7.1 Recent Developments - Importance and How to Use This Section
    • 7.1.1 Importance of These Developments
    • 7.1.2 How to Use This Section
  • 7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform
  • 7.3 Roche receives FDA clearance for STI at POC
  • 7.4 Smartphone-Enabled Platform Transforms POC Testing
  • 7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch
  • 7.6 A low-cost CRISPR-based paper strip test for flu
  • 7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel
  • 7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech
  • 7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/25
  • 7.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact
  • 7.11 DiagMetrics Developing Breath Assays
  • 7.12 Fortis Life Sciences Acquires IPOC
  • 7.13 Domus Diagnostics Wins NIH RADx Tech Contract
  • 7.14 Llusern Scientific to Launch POC MDx UTI Panel
  • 7.15 Altratech Enters POC MDx Testing Space with Unique Tech
  • 7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach
  • 7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System
  • 7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR
  • 7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit
  • 7.20 NanoDx Prepares for Point-of-Care Commercialization
  • 7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection
  • 7.22 MicroGEM to Expand 30-Minute RT-PCR System
  • 7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument
  • 7.24 Diagnostics for the Real World Third-Generation POC Platform
  • 7.25 Salignostics Closes Funding Round
  • 7.26 Cue Health Targets DTC Market in 2022
  • 7.27 Grip Molecular Developing Home Respiratory Panel
  • 7.28 Mainz Biomed Developing Home ColoAlert Assay
  • 7.29 MFB Fertility Closes Series A Financing Round
  • 7.30 Home Test Company Prenetics to go Public
  • 7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.33 Talis Biomedical Discusses Point-of-Care
  • 7.34 Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.36 Hologic to Acquire Mobidiag
  • 7.37 Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.41 Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.43 Scanogen Developing 90 Minute Infection Test
  • 7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.49 Lumos Diagnostics Closes $15M Series A Funding

8 The Global Market for Molecular Diagnostics at the Point of Care

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - End Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segments Growth
  • 8.3 Global Market by Technology - Overview
    • 8.3.1 Table - Global Market by Technology
    • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Technology - Base Year
    • 8.3.4 Chart - Global Market by Technology - End Year
    • 8.3.5 Chart - Global Market by Technology - Share by Year
    • 8.3.6 Chart - Global Market by Technology - Segments Growth
  • 8.4 Global Market by Place - Overview
    • 8.4.1 Table - Global Market by Place
    • 8.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Place - Base Year
    • 8.4.4 Chart - Global Market by Place - End Year
    • 8.4.5 Chart - Global Market by Place - Share by Year
    • 8.4.6 Chart - Global Market by Place - Segments Growth
  • 8.5 Global Market by Product - Overview
    • 8.5.1 Table - Global Market by Product
    • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.5.3 Chart - Global Market by Product - Base Year
    • 8.5.4 Chart - Global Market by Product - End Year
    • 8.5.5 Chart - Global Market by Product - Share by Year
    • 8.5.6 Chart - Global Market by Product - Segments Growth

9 Global MDx at the Point of Care Markets - By Application

  • 9.1 Respiratory Infectious Disease
    • 9.1.1 Table Respiratory Infectious Disease - by Country
    • 9.1.2 Chart - Respiratory Infectious Disease Growth
  • 9.2 Gastrointestinal Infectious Disease
    • 9.2.1 Table Gastrointestinal Infectious Disease - by Country
    • 9.2.2 Chart - Gastrointestinal Infectious Disease Growth
  • 9.3 Sexually Transmitted Disease
    • 9.3.1 Table Sexually Transmitted Disease - by Country
    • 9.3.2 Chart - Sexually Transmitted Disease Growth
  • 9.4 Other Application
    • 9.4.1 Table Other Application - by Country
    • 9.4.2 Chart - Other Application Growth

10 Global MDx Markets at the Point of Care - by Technology

  • 10.1 PCR
    • 10.1.1 Table PCR - by Country
    • 10.1.2 Chart - PCR Growth
  • 10.2 NGS/Probe
    • 10.2.1 Table NGS/Probe - by Country
    • 10.2.2 Chart - NGS/Probe Growth
  • 10.3 Other Technology
    • 10.3.1 Table Other Technology - by Country
    • 10.3.2 Chart - Other Technology Growth

11 Global MDx at the Point of Care Markets - by Place

  • 11.1 Hospital Point of Care
    • 11.1.1 Table Hospital Point of Care - by Country
    • 11.1.2 Chart - Hospital Point of Care Growth
  • 11.2 Clinic or Physician Office Lab
    • 11.2.1 Table Clinic or Physician Office Lab - by Country
    • 11.2.2 Chart - Clinic or Physician Office Lab Growth
  • 11.3 Seniors Facility
    • 11.3.1 Table Seniors Facility - by Country
    • 11.3.2 Chart - Seniors Facility Growth
  • 11.4 Other Place
    • 11.4.1 Table Other Place? by Country
    • 11.4.2 Chart - Other Place Growth

12 Global MDx at the Point of Care Markets - by Product

  • 12.1 Instrument
    • 12.1.1 Table Instrument - by Country
    • 12.1.2 Chart - Instrument Growth
  • 12.2 Cartridge
    • 12.2.1 Table Cartridge - by Country
    • 12.2.2 Chart - Cartridge Growth
  • 12.3 Other Product
    • 12.3.1 Table Other Product - by Country
    • 12.3.2 Chart - Other Product Growth

13 Appendices

  • 13.1 Growth of Approved IVD Test Menu
  • 13.2 Growth of Approved Average IVD Test Fee
  • 13.3 The Most Used IVD Assays
  • 13.4 The Highest Grossing Assays
  • 13.5 Laboratory Fees Schedule

Table of Tables

  • Table 1 Seven Key Diagnostic Laboratory Technology Trends
  • Table 2 Market Players by Type
  • Table 3 Clinical Laboratory Departments and Segments
  • Table 4 Laboratory Management Focus - Different Approaches
  • Table 5 Key Segmentation Variables Going Forward
  • Table 6 Five Factors Driving Growth
  • Table 7 Four Factors Limiting Growth
  • Table 8 - Global Market by Region
  • Table 9 Global Market by Application
  • Table 10 Global Market by Technology
  • Table 11 Global Market by Place
  • Table 12 Global Market by Product
  • Table 13 Respiratory Infectious Disease by Country
  • Table 14 Gastrointestinal Infectious Disease by Country
  • Table 15 Sexually Transmitted Disease by Country
  • Table 16 Other Application by Country
  • Table 17 PCR by Country
  • Table 18 NGS/Probe by Country
  • Table 19 Other Technology by Country
  • Table 20 Hospital Point of Care by Country
  • Table 21 Clinic or Physician Office Lab by Country
  • Table 22 Seniors Facility by Country
  • Table 23 Other Place by Country
  • Table 24 Instrument by Country
  • Table 25 Cartridge by Country
  • Table 26 Other Product by Country
  • Table 27 The Most Common Assays
  • Table 28 Largest Revenue Assays
  • Table 29 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Healthcare Spending
  • Figure 2 Centralized vs. Decentralized Laboratory Service
  • Figure 3 A Highly Multiplexed Syndromic Testing Unit
  • Figure 4 The Real Cost to Sequence the Human Genome
  • Figure 5 The Codevelopment Process
  • Figure 6 The Road to Diagnostics
  • Figure 7 Percentage of World Population Over 65
  • Figure 8 Chart Infectious Disease Decline
  • Figure 9 Global Market Shares Chart
  • Figure 10 Global Market by Application - Base vs. Final
  • Figure 11 Global Market by Application Base Year
  • Figure 12 Global Market by Application End Year
  • Figure 13 Application Share by Year
  • Figure 14 Application Segments Growth
  • Figure 15 Global Market by Technology - Base vs. Final
  • Figure 16 Global Market by Technology Base Year
  • Figure 17 Global Market by Technology End Year
  • Figure 18 Technology Share by Year
  • Figure 19 Technology Segments Growth
  • Figure 20 Global Market by Place - Base vs. Final
  • Figure 21 Global Market by Place Base Year
  • Figure 22 Global Market by Place End Year
  • Figure 23 Place Share by Year
  • Figure 24 Place Segments Growth
  • Figure 25 Global Market by Product - Base vs. Final
  • Figure 26 Global Market by Product Base Year
  • Figure 27 Global Market by Product End Year
  • Figure 28 Product Share by Year
  • Figure 29 Product Segments Growth
  • Figure 30 Respiratory Infectious Disease Diagnostics Growth
  • Figure 31 Gastrointestinal Infectious Disease Growth
  • Figure 32 Sexually Transmitted Disease Growth
  • Figure 33 Other Application Growth
  • Figure 34 PCR Growth
  • Figure 35 NGS/Probe Growth
  • Figure 36 Other Technology Growth
  • Figure 37 Hospital Point of Care Growth
  • Figure 38 Clinic or Physician Office Lab Growth
  • Figure 39 Seniors Facility Growth
  • Figure 40 Other Place Growth
  • Figure 41 Instrument Growth
  • Figure 42 Cartridge Growth
  • Figure 43 Other Product Growth
  • Figure 44 IVD Test Menu Growth
  • Figure 45 IVD Test Average Fees - A Ten Year View